Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna, Italy.
Department of Pathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna, Italy.
Pathol Res Pract. 2021 Apr;220:153410. doi: 10.1016/j.prp.2021.153410. Epub 2021 Mar 18.
In recent years, HER2 amplification has been evaluated as a potential prognostic biomarker and therapeutic target in urothelial carcinoma (UC). In this retrospective study, we aimed at exploring the prognostic role of HER2 amplification in UC, measured by chromogenic in situ hybridization (CISH).
We retrospectively evaluated the presence of HER2 amplification by using CISH in 31 UC patients followed at a single institution between 2018 and 2020. The primary objective was to assess the frequency of HER2 amplification and to compare clinical outcomes of HER2-amplified patients with non-amplified UCs.
HER2 amplification was identified in 4 out of 31 patients (12.9 %). After a median follow-up of 28.1 months (95 % Confidence Intervals [CI] 11.2-45.1), median overall survival (OS) in the whole population was 10.9 months (95 % CI 3.5-22.1). Despite not reaching statistical significance, median OS was shorter in HER2-amplified patients (6.8 months, 95 % CI 3.9-9.7) compared to HER2-negative UCs (15.4 months, 95 % CI 7.5-23.3) (p = 0.45).
Although limited by the small sample size, the results of our study suggest that HER2 amplifications by CISH could represent a prognostic factor for shorter survival in UC patients.
近年来，HER2 扩增已被评估为尿路上皮癌（UC）的一种潜在预后生物标志物和治疗靶点。在这项回顾性研究中，我们旨在通过显色原位杂交（CISH）评估 HER2 扩增在 UC 中的预后作用。
我们回顾性评估了 31 例在 2018 年至 2020 年在一家机构接受治疗的 UC 患者中使用 CISH 检测 HER2 扩增的情况。主要目的是评估 HER2 扩增的频率，并比较 HER2 扩增患者与非扩增 UC 的临床结局。
在 31 例患者中有 4 例（12.9%）发现 HER2 扩增。在中位随访 28.1 个月（95%置信区间 [CI] 11.2-45.1）后，全人群的中位总生存期（OS）为 10.9 个月（95%CI 3.5-22.1）。尽管没有达到统计学意义，但与 HER2 阴性 UC 相比，HER2 扩增患者的中位 OS 更短（6.8 个月，95%CI 3.9-9.7）（p=0.45）。
尽管样本量较小，但本研究结果表明，CISH 检测的 HER2 扩增可能是 UC 患者生存时间较短的预后因素。
